Recommended models: Haile Miao, Haile Pet
 
Founded in 1956, Hisun Pharmaceutical Co., Ltd. is mainly engaged in APIs, innovative drugs, animal health and other businesses, and in 2012, Hisun Pfizer Pharmaceutical Co., Ltd. was established as a joint venture with Pfizer in the field of branded generic drugs.
 
Hisun Pharmaceutical entered the pet drug industry in 2016, and its pet deworming drug products are Haile Miao and Haile Pet, the former is used for cats, and the latter is used for dogs, with similar active ingredients, but the range of Haile Miao deworming for cats is wider, and Haile Pet for dogs is ineffective against tapeworms and flukes because it only has a single mil oxime component.
 
Careful people may find that the content of the formula table of Haile Miao is the same as that of Novartis in Switzerland, such as the active ingredients used in kittens are "Milbemycin Oxime (4mg) and Praziquantel (Praziquantel) 10mg", and the dosage is also the same, which can be considered as a generic drug of Miaoba.
 
As mentioned above, in drug research and development, even if the ingredients of generic drugs are consistent, they may not be able to achieve the effect of the original drug. According to the experimental analysis of Jin Zhiyuan et al. from the School of Veterinary Medicine of Yangzhou University, the milberoxime praziquantel tablets produced by Novartis and the ones produced by Hisun Pharmaceutical have similar pharmacokinetic characteristics and similar efficacy after oral administration in cats. According to the official website of the US FDA, Hisun Pharmaceutical has obtained the relevant VMF number (veterinary drug license), and in China, Hisun Pharmaceutical has also obtained the China GMP license. Therefore, from various data, we can analyze that Haile Miao is already a relatively successful generic drug.
 
As a high-end pet drug, Milbexime has been used abroad for more than 20 years, but it is less widely used in China. The United States accounts for about 70% of the global market for mibeloxime, and the European market accounts for about 20%.